This post may refer to COVID-19
To access official information about the coronavirus, access CDC - Centers for Disease Control and Prevention.
www.reuters.com
Two Indian drugmakers seek to end trials of Merck's antiviral drug for moderate COVID-19
Two Indian drugmakers have requested permission to end their late-stage trials on Merck & Co's experimental antiviral drug molnupiravir in moderate COVID-19 patients.
Health
BENGALURU, Oct 8 (Reuters) - Two Indian drugmakers have requested permission to end their late-stage trials on Merck & Co's (MRK.N) experimental antiviral drug molnupiravir in moderate COVID-19 patients.
The two Indian drugmakers, Aurobindo Pharma Ltd (ARBN.NS) and MSN Laboratories plan to continue late-stage trails of the drug for those with mild COVID-19, the Indian drug regulator's expert committee said on Friday.
The two companies separately sought permission to end trials in the case of moderate COVID-19 patients after having submitted interim clinical trial data around the effectiveness of the drug in treating this category of patients, the committee disclosed, throwing into question the efficacy of the experimental drug in improving outcomes for patients with moderate cases of COVID-19.
Separately, a senior source at India's drug regulator told Reuters that molnupiravir had shown no "significant efficacy" against moderate COVID-19 cases.